According to a long-awaited study led by key proponents of so-called “gender violation care,” the use of adolescent blockers has no statistically significant effect on depression rates in via-identified youth suffering from gender discomfort.
Advocacy group Genspect described it as “an international alliance promoting a demedical approach to sex and gender,” and published a post on Thursday, highlighting that “long-repressed Olson-Kennedy’s research on adolescent blockers finally came out.”
Adolescent blockers are often prescribed to children who show gender discomfort to stop natural adolescence.
The study attracted media attention last year, a supporter of minor gender transition procedures, Dr. Johanna Olson Kennedy, the lead author, and advocate for minor gender transition procedures, which attracted media attention for political reasons.
“I don’t want to use our work as a weapon,” she expressed concern last year to the New York Times, saying it could be used in court to insist that “blockers should not be used.”
The Olson-Kennedy study, released on May 15th and yet to be peer-reviewed, examined the mental health of 94 young people with gender discomfort at six-month intervals after finishing two years later, first starting adolescence blockers.
“Self-reported symptoms of depression did not change significantly over a 2-year follow-up period in both conditional and unconditional growth models,” the study concluded.
Data are based on participants’ scores on various mental health ratings. In the Beck depression catalogue, called “20-item self-report judges of depression symptoms over the past two weeks,” participants’ mean T-scores were 48.45 at the start of the study. A T-score below 55 indicates the average level of depression symptoms, while a higher T-score indicates an increase in depression symptoms.
After 6 months with adolescent blockers, the average T-score increased slightly to 49.85. Mean T-scores were measured at 48.43, 49.88, and 49.39 at 12 months, 18 months and 2 years respectively on adolescent blockers.
“At baseline, 72% of participants (n = 63) had an average BDI-Y score, 10% (n = 9) had a mild rise, 10% (n = 9) had a moderate rise, and 8% (n = 7) had a severe rise,” the report states. “At 24 months (n = 59), 75% of participants (n = 42) had a mild rise in average BDI-Y score, 7% (n = 4) and moderate rise in 14% (n = 8) and 9% (n = 5) had a significant increase in scores.”
However, in this study, participants determined that they were less likely to have attempted suicide two years later with adolescent blockers than they began the study.
“At baseline, 20 participants reported experiencing suicidal ideation, 11 participants approved suicidal ideation in the past six months, three participants made a suicide plan in the past six months, and two participants reported suicide attempts in the past six months.
“In a 24-month follow-up, five participants approved suicidal ideation in the last six months and one participant reported suicide attempts in the last six months, which did not result in medically necessary injuries,” the report states.
In a post in response to the study, Genspect said the results “have no significant improvement in depression, emotional health, or parental reported behavior.”
“Another way, the results of the Netherlands research could not be replicated,” the group noted.
Christian post-social commentator Brandon Shorterter is the host of the “Gender Inquiry” podcast series, and says Olson-Kennedy is “communicating” the release of the study.
“All ‘studies’, which aims to demonstrate the potential benefits of adolescent blockers of gender-confused minors regarding suicide, must take into account the irreparable, flawed premise of so-called ‘gender-affirming care’.
“In the coming years, minor transing will continue to prove to be one of the most frightening medical scandals in history and suspicious child abuse,” he predicted.
“We must also remember that the FOIA-covered document shows that in the course of this grossly unethical study she will change the protocol midway through, lowering the age of the hormone inclusion standard by half from 13 to 8.”
About 20 states have banned trans-identified youths from acquiring adolescent blockers and sex crosshormones due to concerns about long-term impact. The American University of Pediatricians lists potential side effects of adolescent blockers as “sterile when combined with osteoporosis, mood disorders, seizures, cognitive impairments, and cross-sex hormones.”
Most of the actions to crack down on adolescent blockers and other types of gender transition procedures were taken at the state level, but it changed when President Donald Trump signed an executive order that declared “it’s a US policy, and that children from “children” suffered from other lawsuits and declared “promotion, promotion, promotion, support, or support” and declared this was a US policy. Life-changing steps. ”
Trump’s executive order directed the head of the administration to “take appropriate measures to ensure that agencies receiving federal research or education grants end chemical and surgical amputations in children” and “retract or modify all policies.”
Originally published by The Christian Post
